Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon extension in Huntington disease
NCT01085266Phase 3
Key facts
- Status
- Terminated
- Start
- Feb 2010
- Primary completion
- Jun 2011
- Sponsor
- Medivation
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Drugs
- latrepirdine
- Conditions
- Huntington disease (HD)
01
Overview
Phase 3, open-label, single-arm trial of latrepirdine in Huntington disease (HD), sponsored by Medivation. Primary endpoint: Safety and Tolerability. Started Feb 2010; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Dimebon (latrepirdine)
Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
03
Who it enrols
Patients who successfully completed 26 weeks of blinded treatment in the HORIZON study.
04
Endpoints
Primary
Safety and Tolerability
Beyond the preview
Go deeper on NCT01085266.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085266.